Alves-Silva Jorge M, Zuzarte Mónica, Marques Carla, Viana Sofia, Preguiça Inês, Baptista Rui, Ferreira Cátia, Cavaleiro Carlos, Domingues Neuza, Sardão Vilma A, Oliveira Paulo J, Reis Flávio, Salgueiro Lígia, Girão Henrique
Univ Coimbra, Faculty of Pharmacy, Coimbra, Portugal; Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, Coimbra, Portugal; Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal.
Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, Coimbra, Portugal; Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal; Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal.
Pharmacol Res. 2022 Jun;180:106151. doi: 10.1016/j.phrs.2022.106151. Epub 2022 Mar 2.
For the first time, the present study unravels a cardiospecific therapeutic approach for Pulmonary Arterial Hypertension (PAH), a disease with a very poor prognosis and high mortality rates due to right ventricle (RV) dysfunction. We first established a new in vitro model of high-pressure-induced hypertrophy that closely resembles heart defects associated with PAH and validated our in vitro findings on a preclinical in vivo model of monocrotaline (MCT)-induced PAH. Our results showed the in vitro antihypertrophic effect of 1,8-cineole, a monoterpene widely found in several essential oils. Also, a decrease in RV hypertrophy and fibrosis, and an improvement in heart function in vivo was observed, when 1,8-cineole was applied topically. Furthermore, 1,8-cineole restored gap junction protein connexin43 distribution at the intercalated disks and mitochondrial functionality, suggesting it may act by preserving cardiac cell-to-cell communication and bioenergetics. Overall, our results point out a promising therapeutic compound that can be easily applied topically, thus paving the way for the development of effective cardiac-specific therapies to greatly improve PAH outcomes.
本研究首次揭示了一种针对肺动脉高压(PAH)的心脏特异性治疗方法。PAH是一种预后极差、因右心室(RV)功能障碍导致死亡率很高的疾病。我们首先建立了一种新的体外高压诱导肥大模型,该模型与PAH相关的心脏缺陷非常相似,并在单氰胺(MCT)诱导的PAH临床前体内模型上验证了我们的体外研究结果。我们的结果显示了1,8-桉叶素(一种在多种香精油中广泛存在的单萜)的体外抗肥大作用。此外,当局部应用1,8-桉叶素时,观察到体内RV肥大和纤维化减少,心脏功能改善。此外,1,8-桉叶素恢复了闰盘处缝隙连接蛋白连接蛋白43的分布和线粒体功能,表明它可能通过维持心脏细胞间通讯和生物能量学发挥作用。总体而言,我们的结果指出了一种有前景的治疗化合物,它可以很容易地局部应用,从而为开发有效的心脏特异性疗法以大大改善PAH的治疗效果铺平道路。